Trials / Terminated
TerminatedNCT04870164
Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)
A Phase 1, First-time-in-human, Dose Ascending Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MP0420 (a Novel Drug Candidate With Potential for Treatment of COVID-19) in Healthy Volunteers
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- Molecular Partners AG · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study will investigate how ensovibep is distributed throughout the body, the safety and the tolerability of ensovibep in healthy volunteers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ensovibep | The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohorts. 3 IV infusion, 2 IV bolus, 4 subcutaneous and 4 intramuscular cohorts are planned. Subjects receive one or two administration(s) on day 1, depending on the cohort. |
| DRUG | Placebo | One administration at day 1 by infusion. |
Timeline
- Start date
- 2020-11-18
- Primary completion
- 2022-01-06
- Completion
- 2022-01-06
- First posted
- 2021-05-03
- Last updated
- 2022-03-18
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04870164. Inclusion in this directory is not an endorsement.